SSA
NVCR icon

Schonfeld Strategic Advisors’s NovoCure NVCR Stock Holding History

Schonfeld Strategic Advisors’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-55,000
Closed -$393K – 2469
2022
Q4 		$393K Buy
+55,000
New +$4.14M ﹤0.01% 1664

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
QCM
Quantinno Capital Management New York $59.9B AUM 28.07% 1-Year Est. Return

Schonfeld Strategic Advisors's NVCR Position: Q1 2026 in Review

Schonfeld Strategic Advisors sold out of NovoCure (NVCR) in Q1 2026, closing a stake of 144,728 shares — an estimated $1.87M sold.

Schonfeld Strategic Advisors first reported a position in NVCR in Q3 2019 and held it in 13 quarters. The position peaked at $5.69M in Q1 2024. 222 funds tracked by Wall St. Rank hold NVCR as of Q1 2026.

  • Schonfeld Strategic Advisors reported no remaining NovoCure position as of Q1 2026 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 144,728 NovoCure shares in Q1 2026, an estimated $1.87M.
  • Schonfeld Strategic Advisors first reported a position in NovoCure in Q3 2019 and held it in 13 quarters.
  • Schonfeld Strategic Advisors's NovoCure position peaked at $5.69M in Q1 2024.
  • 222 funds tracked by Wall St. Rank held NovoCure as of Q1 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q1 2026, filed 15 May 2026.